Mycotherapy: Beyond the “Immune-Boosting” Narrative
Medicinal mushrooms are more interesting than the claims made about them.
Medicinal mushrooms are frequently presented as natural substances capable of boosting the immune system. The expression appears everywhere, from supplement descriptions to conversations about preventive health and integrative medicine.
It sounds reassuring. After all, who wouldn’t want a stronger immune system?
But the more closely we examine immunology, the less useful that description becomes.
An effective immune system needs to recognise potential threats, coordinate appropriate responses, distinguish between harmful and harmless stimuli, and eventually resolve inflammatory activity when it is no longer needed.
Increasing immune activity indiscriminately would hardly be a desirable therapeutic objective.
An insufficient immune response can leave an organism vulnerable to infection. An excessive or poorly regulated response can contribute to inflammation and tissue damage. And in immune-mediated diseases, the problem may involve the immune system reacting inappropriately to the organism’s own tissues.
This is one of the reasons I find the usual language surrounding medicinal mushrooms rather unsatisfactory.
It reduces a remarkably complex area of biology to the idea that more immune activity must somehow be better.
The research itself is considerably more interesting.
What are we actually studying?
The term medicinal mushrooms encompasses a diverse group of fungi whose constituents have attracted scientific interest for their potential biological activities.
Among the most extensively discussed compounds are beta-glucans, a heterogeneous group of polysaccharides found in fungal cell walls.
Certain beta-glucans can interact with receptors involved in innate immune recognition, and experimental studies have investigated how these interactions influence immune signalling and cellular responses.
But beta-glucans are not all structurally identical. Their molecular characteristics vary, and those differences can influence biological activity.
This becomes relevant when we consider the products marketed as mushroom extracts.
Two preparations derived from the same fungal species may differ in composition depending on cultivation conditions, the part of the fungus used, extraction methods, processing and standardisation.
And beta-glucans represent only part of the picture.
Some fungi, including species belonging to the genus Ganoderma, contain triterpenoids that have been investigated for a variety of biological activities. Phenolic compounds and other metabolites have also attracted attention because of their biochemical properties.
The diversity is substantial.
It also makes generalisations difficult.
When someone refers to the benefits of a medicinal mushroom, I think it is reasonable to ask which species, which preparation, which compounds and which biological effects they are actually referring to.
Without those distinctions, the conversation can become surprisingly vague.
The immune system is not working alone
Another reason mycotherapy interests me is the relationship between immune function and other physiological systems.
Immune signalling is closely connected to metabolism, intestinal physiology and the activity of microbial communities.
The gastrointestinal tract is particularly relevant because it represents an important interface between the organism and its external environment. It is involved in nutrient processing, barrier function, microbial interactions and immune regulation.
Research involving fungal polysaccharides and other mushroom-derived compounds has explored several aspects of these relationships.
Some experimental investigations examine interactions with immune cells. Others explore changes in microbial communities, inflammatory signalling or metabolic responses.
These findings offer different ways of studying how fungal constituents may interact with biological systems.
However, the existence of these interactions does not establish that a particular mushroom preparation will produce a predictable therapeutic benefit.
A change in a laboratory marker, for example, may be biologically interesting without necessarily translating into an improvement in health.
Likewise, an effect observed in an experimental model may depend on conditions that are very different from those encountered in a clinical patient.
The organism is not a collection of isolated pathways, and the effects of a compound cannot always be predicted by studying one mechanism in isolation.
This complexity is part of what makes the field worth investigating.
It is also why interpreting the findings requires care.
What laboratory research can tell us — and what it cannot
One difficulty in discussing medicinal mushrooms is that research findings from very different levels of evidence are often presented together.
Get Viola Vannucci’s stories in your inbox
Join Medium for free to get updates from this writer.
A compound may demonstrate an effect on cultured cells. A preparation may influence a physiological parameter in an experimental animal model. A clinical study may investigate whether an intervention improves a meaningful outcome in patients with a particular condition.
These observations answer different questions.
Laboratory research can help identify mechanisms and generate hypotheses about biological activity.
Preclinical studies may provide information about how a compound behaves in a more complex biological setting, including aspects of safety, metabolism and physiological response.
Clinical studies are needed to determine whether a particular intervention offers meaningful benefits to the population for which it is intended.
For veterinary medicine, this distinction is especially important.
Evidence obtained from human studies cannot automatically be transferred to dogs, cats, horses or other species.
Differences in metabolism, physiology, susceptibility to adverse effects and disease characteristics may all influence the response to a preparation.
Even when a mechanism appears plausible, we still need to understand whether the product can produce the relevant effect at an appropriate dose, whether it is safe, and whether the outcome matters clinically.
I sometimes find that discussions about integrative medicine become polarised around two positions.
On one side, experimental findings are treated as though they already establish therapeutic efficacy. On the other, research that has not yet reached the stage of definitive clinical validation is dismissed as irrelevant.
Neither approach is particularly helpful when trying to understand an emerging field.
A laboratory observation may provide a legitimate reason for further investigation. It may also turn out to have little practical clinical significance.
The purpose of research is precisely to establish which possibilities withstand closer examination.
The problem with treating every mushroom extract as equivalent
There is another issue that deserves attention, especially when discussing clinical applications.
A mushroom extract is a biochemical preparation.
Its composition matters.
The fungal species, the material used, the extraction process and the concentration of relevant constituents can all influence what the final product contains.
This means that findings obtained with one preparation cannot necessarily be applied to another, even when both are marketed under the same mushroom name.
The question of standardisation becomes particularly important when products are intended for therapeutic use.
If we do not know what a preparation contains, or how consistently it is manufactured, interpreting its potential biological effects becomes difficult.
Safety also needs to be considered.
Natural origin does not guarantee that a substance is harmless, particularly in animals with underlying diseases or those receiving other treatments.
Possible adverse effects, interactions, product quality and species-specific considerations are all relevant to clinical decision-making.
For these reasons, I would be cautious about approaching mycotherapy through generic protocols or assuming that a particular mushroom is suitable for every patient with a broadly defined condition.
The clinical context matters too much.
Where I stand on mycotherapy
I consider medicinal mushrooms a legitimate area of interest within integrative veterinary medicine.
Their biochemical diversity, together with the range of physiological processes being investigated, makes them an interesting subject for research.
What attracts my attention is the possibility of studying their interactions with immune regulation, intestinal physiology, metabolism and other biological processes.
I am much less interested in the idea of stimulating the immune system as an isolated therapeutic objective.
At the same time, the available evidence is uneven.
Some fungal constituents have been investigated extensively in experimental settings, while many proposed clinical applications remain insufficiently established, particularly in veterinary patients.
That distinction influences how I think these preparations should be discussed.
There is room for curiosity, for mechanistic research and for carefully designed clinical studies. There may also be circumstances in which a particular preparation deserves consideration within an individual patient’s management, provided that the available evidence, safety profile and intended objective justify it.
But those decisions require considerably more specificity than the label immune-boosting mushroom can provide.
Which preparation are we discussing? What is known about its composition? What evidence exists in the relevant species? What outcome are we hoping to influence, and how would we evaluate whether the intervention is actually helping?
These are the questions I would want to answer before drawing clinical conclusions.
The field of mycotherapy is interesting enough without needing to exaggerate what has already been demonstrated.
And I suspect that moving beyond the familiar promises of immune boosting would allow for a much more useful conversation about what medicinal mushrooms may — or may not — eventually contribute to veterinary medicine.
